Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months.

Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months.

Publication date: Jun 05, 2026

SARS-CoV-2 infection triggers a strong inflammatory response, and persistent symptoms after recovery are thought to reflect prolonged systemic dysregulation. However, mechanisms underlying long COVID remain unclear. This study evaluated longitudinal changes in cytokine hematological and biochemical parameters up to nine months after hospitalization for COVID-19 and examined their relationship with persistent symptoms, vaccination status, and the occurrence of comorbidities. Long COVID patients showed sustained elevations in IL-2, IL-6, IL-10, IL-17A, CXCL9, TNF-α, and IFN-γ compared with healthy controls, exhibiting heterogeneous temporal trajectories. Specifically, levels of IL-2, IL-10, TNF-α, and creatinine continued to increase over time, whereas IFN-γ, LDH, CCL2, CXCL9, and CXCL10 declined. Other parameters exhibited greater variability without a uniform longitudinal pattern. IL-6 demonstrated consistently high diagnostic performance in distinguishing individuals after COVID-19 from healthy controls (AUC > 0. 82). Aging substantially affects cytokine profiles and systemic inflammatory status; therefore, residual age-related confounding cannot be fully excluded despite statistical adjustment. Although symptoms such as fatigue, cough, and dyspnea were still reported at nine months, no stable associations were identified between cytokine concentrations and clinical manifestations. These findings indicate that while immune alterations persist long after acute infection, systemic cytokine measurements alone may be insufficient to explain the presence or persistence of symptoms. The results suggest that long COVID reflects multifactorial processes extending beyond systemic inflammation and highlight the need for further research into mechanisms driving long-term long COVID sequelae.

Open Access PDF

Concepts Keywords
Cxcl10 Aged
Driving biomarkers
Healthy COVID-19
Hematological COVID-19
Inflammatory cytokine storm
Cytokines
Cytokines
disease severity
Female
Humans
immune dysregulation
Longitudinal Studies
Male
Middle Aged
Post-Acute COVID-19 Syndrome
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH long COVID
drug DRUGBANK Interleukin-10
drug DRUGBANK Creatinine
disease MESH fatigue
disease MESH cough
disease MESH dyspnea
disease MESH infection
disease MESH inflammation
disease MESH Kos
disease MESH Infectious Diseases
disease MESH cytokine storm
disease MESH severe acute respiratory syndrome
disease MESH pneumonia
disease MESH clinical deterioration
disease MESH acute respiratory distress syndrome
disease MESH injury
disease MESH syndromes
disease MESH influenza
disease MESH thrombocytopenia
disease MESH agranulocytosis
disease MESH hypertension
disease MESH overweight
disease MESH death
disease MESH Obesity
disease MESH Asthma
pathway KEGG Asthma
disease MESH Hypothyroidism
disease MESH Atrial fibrillation
disease MESH Prostatic hyperplasia
disease MESH Multiple sclerosis
disease MESH Depressive disorder
disease MESH diabetes mellitus
disease MESH abdominal obesity
disease MESH coronary artery disease
disease MESH PCT
drug DRUGBANK Saquinavir
disease MESH dis
disease MESH included
disease MESH fibrosis
disease MESH convalescence
drug DRUGBANK Carbon monoxide
drug DRUGBANK Iron
disease MESH reinfection
disease MESH respiratory infections
drug DRUGBANK Oxygen
disease MESH sepsis
disease MESH septic shock
drug DRUGBANK Coenzyme M
drug DRUGBANK Etoperidone
drug DRUGBANK Carboxyamidotriazole
disease MESH Thrombosis
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Hyperlipidemia
disease MESH Pulmonary Function
disease MESH Bacterial Pneumonia
pathway REACTOME Immune System
disease MESH Allergy

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *